In this study, the investigators will examine the effect of therapy with the Growth Hormone
Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV
lipodystrophy and central adiposity. This study is a single arm prospective study of
tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition
testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity
assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous
injection.
Phase:
Phase 4
Details
Lead Sponsor:
Columbia University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)